Keros Therapeutics (KROS) Non Operating Income (2019 - 2025)
Keros Therapeutics (KROS) reported Non Operating Income of $273000.0 for Q4 2025, up 101.59% on a YoY basis from $135425.6 in Q4 2024, and up 207.91% quarter-over-quarter from -$253000.0 in Q3 2025.
Keros Therapeutics (KROS) Non Operating Income (2019 - 2025) Analysis & Trends
Keros Therapeutics has reported Non Operating Income for 7 years, with the latest figure at $273000.0 in Q4 2025.
- For the quarter ending Q4 2025, Non Operating Income rose 101.59% year-over-year to $273000.0; the trailing twelve-month figure through Dec 2025 stood at $6.6 million (up 197.35% YoY), and the FY2025 full-year result was -$539000.0, up 43.5% from the prior year.
- Non Operating Income for Q4 2025 stood at $273000.0, up from -$253000.0 in the prior quarter.
- The five-year high for Non Operating Income was $9.3 million in Q4 2022, with the low at -$17.2 million in Q4 2024.
- Historically, Non Operating Income has averaged $269050.0 across 5 years, with a median of -$62000.0 in 2021.
- Annual changes were most pronounced in 2022 — Non Operating Income soared 12529.33% — and 2023, when it tumbled 280.23%.
- Keros Therapeutics' Non Operating Income stood at -$75000.0 in 2021, then soared by 12529.33% to $9.3 million in 2022, then sank by 217.39% to -$10.9 million in 2023, then plunged by 57.23% to -$17.2 million in 2024, then soared by 101.59% to $273000.0 in 2025.
- The last three Non Operating Income figures came in at $273000.0 (Q4 2025), -$253000.0 (Q3 2025), and $6.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Keros Therapeutics | 399.01 Mn | 111.61 Mn | - | 273,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 273,000.00 |
| Sep 30, 2025 | -253,000.00 |
| Jun 30, 2025 | 6.90 Mn |
| Mar 31, 2025 | -338,000.00 |
| Dec 31, 2024 | -17.21 Mn |
| Sep 30, 2024 | 5.70 Mn |
| Jun 30, 2024 | 5.18 Mn |
| Mar 31, 2024 | -437,000.00 |
| Dec 31, 2023 | -10.94 Mn |
| Sep 30, 2023 | 3.84 Mn |
| Jun 30, 2023 | -155,000.00 |
| Mar 31, 2023 | 3.07 Mn |
| Dec 31, 2022 | 9.32 Mn |
| Sep 30, 2022 | 762,000.00 |
| Jun 30, 2022 | 86,000.00 |
| Mar 31, 2022 | -59,000.00 |
| Dec 31, 2021 | -75,000.00 |
| Sep 30, 2021 | -138,000.00 |
| Jun 30, 2021 | -80,000.00 |
| Mar 31, 2021 | -65,000.00 |